MTL
0.002
100%
4DS
0.009
-67.9%
ANR
0.013
62.5%
JAV
0.002
-33.3%
CHM
0.003
50%
M4M
0.007
-22.2%
KRR
0.01
42.9%
QXR
0.004
-20%
LAT
0.065
38.3%
SIS
0.004
-20%
SP3
0.032
33.3%
THR
0.01
-16.7%
4DX
1.695
29.4%
MGT
0.067
-16.3%
BYH
0.005
25%
LML
0.006
-14.3%
FBR
0.005
25%
M2M
0.018
-14.3%
OEL
0.005
25%
SPX
0.006
-14.3%
PEK
0.417
24.5%
ESR
0.028
-12.5%
SNX
0.039
21.9%
KCCDA
0.875
-12.5%
XGL
0.028
21.7%
PET
0.007
-12.5%
ZMM
0.018
20%
INF
0.015
-11.8%
GML
0.062
19.2%
RGT
0.115
-11.5%
SUH
0.038
18.8%
EMU
0.024
-11.1%
MQR
0.013
18.2%
MGU
0.008
-11.1%
BSN
0.046
17.9%
POD
0.041
-10.9%
ATR
0.54
17.4%
RPG
0.125
-10.7%
RNT
0.041
17.1%
SHN
0.017
-10.5%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

PharmAust (ASX:PAA): Extension study begins

Clinical-stage biotechnology company, PharmAust (ASX:PAA), announces that the first patient has been dosed in the Open-Label Extension study at Calvary Health Care Bethlehem, which will investigate the long-term safety, tolerability and efficacy of monepantel in patients with Motor Neurone Disease.

ASX announcement: https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02772313-6A1193834